tiprankstipranks
Trending News
More News >
Beamtree Holdings Ltd (AU:BMT)
ASX:BMT
Australian Market

Beamtree Holdings Ltd (BMT) AI Stock Analysis

Compare
12 Followers

Top Page

AU:BMT

Beamtree Holdings Ltd

(Sydney:BMT)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 5.2)
Rating:44Neutral
Price Target:
AU$0.16
▼(-27.27% Downside)
Action:ReiteratedDate:02/21/26
The score is primarily driven down by weak financial performance (loss-making operations, negative revenue growth, and cash flow strain) and bearish technical momentum (price below key moving averages with negative MACD). Valuation is only modestly supportive because the negative P/E reflects current losses and dividend yield is unavailable.
Positive Factors
High gross margin
An observed 100% gross profit margin indicates the core product has minimal direct costs, implying a highly scalable software/data business. If revenue growth resumes, this margin profile can translate to strong operating leverage and long-term margin expansion once fixed costs are absorbed.
Conservative balance sheet
The balance sheet displays relatively low leverage and a stable equity ratio, offering financial flexibility. Conservative capital structure provides a cushion to fund product development or absorb operating losses, important given long sales cycles in healthcare IT.
Specialized healthcare data platform
Beamtree's niche focus on clinical terminology, coding and decision support creates high switching costs and deep workflow integration. Structural digitization in hospitals and growth in analytics/quality documentation support durable demand for specialized clinical data platforms.
Negative Factors
Negative operating profitability
Negative EBIT and EBITDA margins show the company remains unprofitable at the operating level. Persistent operating losses erode equity and constrain reinvestment; without sustained revenue improvement or material cost reductions, recovering durable profitability will be difficult.
Weak cash generation
Negative free cash flow growth and weak operating cash conversion point to liquidity strain. Poor cash generation can force dilutive financing or restrict investment in sales and product development, hindering the company’s ability to scale and compete over the medium term.
Revenue growth decline
Reported revenue growth turning negative suggests weakening demand or competitive pressure. Declining top-line reduces ability to leverage fixed costs and fund growth initiatives, raising the risk that operating losses persist and long-term market position erodes.

Beamtree Holdings Ltd (BMT) vs. iShares MSCI Australia ETF (EWA)

Beamtree Holdings Ltd Business Overview & Revenue Model

Company DescriptionBeamtree Holdings Limited develops and commercializes clinical decision support (CDS) systems to healthcare industry in Australia and internationally. The company offers RippleDown Expert, a CDS system that provides real-time patient monitoring and alerting solutions; RippleDown Auditor, that automates real-time reviews of data, ensuring accuracy across data entry, billing, specimen reception, and flagging suspected errors; and PICQ, a coding quality assessment tool for public and private hospitals, health services, and state health departments that assesses and reports clinically coded data. It also provides RISQ, a measurement, benchmarking, and management tool for hospital-acquired complications; Q Coding Platform, an end-to-end workflow suite for clinical coding, grouping, reporting, and auditing; and Codexpert, a searchable eBook application that offers classification reference information for clinical coding patient records. The company offers advisory and auditing solution, such as desktop analysis, data maturity index, and physical audits. It serves customers through channel partners. The company was formerly known as PKS Holdings Limited and changed its name to Beamtree Holdings Limited in August 2021. Beamtree Holdings Limited was founded in 1996 and is headquartered in Redfern, Australia.
How the Company Makes MoneyBeamtree Holdings Ltd generates revenue primarily through the sale of its software solutions and data analytics services to healthcare providers, including hospitals, clinics, and mental health organizations. The company adopts a subscription-based model for many of its products, allowing clients to access its platforms for a recurring fee, which provides predictable revenue streams. Additionally, BMT may earn income through consulting services related to the implementation and optimization of their software. Strategic partnerships with healthcare institutions and technology firms also contribute to its earnings, as they can lead to joint ventures, co-development projects, and expanded market reach.

Beamtree Holdings Ltd Financial Statement Overview

Summary
Financial health is weak: the income statement shows negative profitability (negative EBIT/EBITDA margins) and revenue growth has turned negative. Cash flow is also pressured with negative free cash flow metrics and poor cash conversion. The balance sheet is comparatively steadier with conservative leverage, but negative ROE remains a key concern.
Income Statement
45
Neutral
Beamtree Holdings Ltd shows a concerning trend in its income statement, with negative net profit margins and declining revenue growth. The gross profit margin is strong at 100%, but the company is struggling with negative EBIT and EBITDA margins, indicating operational inefficiencies. The revenue growth rate has turned negative, suggesting a potential decline in market demand or competitive pressures.
Balance Sheet
55
Neutral
The balance sheet reflects a relatively low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, pointing to inefficiencies in generating returns for shareholders. The equity ratio is stable, suggesting a solid capital structure, but the negative ROE is a significant concern.
Cash Flow
40
Negative
Cash flow analysis reveals challenges with negative free cash flow growth and a low operating cash flow to net income ratio. The free cash flow to net income ratio is also negative, highlighting cash generation issues. These factors suggest potential liquidity constraints and the need for improved cash management.
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue28.90M28.60M27.60M22.77M16.55M8.39M
Gross Profit1.66M28.60M4.89M2.14M-202.00K2.77M
EBITDA-4.74M-808.00K-331.00K-1.26M-2.28M1.02M
Net Income-5.78M-6.16M-5.11M-6.91M-4.45M-383.62K
Balance Sheet
Total Assets53.26M54.29M59.65M62.53M63.91M47.05M
Cash, Cash Equivalents and Short-Term Investments2.94M4.78M5.04M8.81M6.35M14.12M
Total Debt3.65M3.26M1.66M755.00K1.12M799.36K
Total Liabilities13.76M12.36M12.52M15.31M15.33M4.96M
Stockholders Equity39.51M41.93M47.14M47.22M48.58M42.09M
Cash Flow
Free Cash Flow906.00K-1.84M-4.51M-1.88M-4.83M-2.64M
Operating Cash Flow1.08M609.00K-492.00K768.00K-2.32M240.65K
Investing Cash Flow-3.37M-2.45M-4.02M-2.65M-5.16M-2.98M
Financing Cash Flow1.54M1.58M749.00K4.34M-286.00K12.65M

Beamtree Holdings Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.22
Price Trends
50DMA
0.17
Negative
100DMA
0.19
Negative
200DMA
0.22
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
40.11
Neutral
STOCH
13.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BMT, the sentiment is Negative. The current price of 0.22 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.17, and above the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.11 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BMT.

Beamtree Holdings Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
AU$141.01M26.514.37%10.06%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
AU$62.28M-6.28-23.86%15.99%22.05%
47
Neutral
AU$19.56M3.957.57%28.91%-1050.00%
45
Neutral
AU$31.35M-3.13-1009.84%25.98%22.10%
44
Neutral
AU$42.14M-5.70-14.19%3.61%-17.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:BMT
Beamtree Holdings Ltd
0.15
-0.11
-42.00%
AU:M7T
Mach7 Technologies
0.27
-0.12
-31.17%
AU:RHT
Resonance Health Ltd
0.04
<0.01
2.50%
AU:ALC
Alcidion Group Limited
0.11
0.02
31.25%
AU:PCK
PainChek Ltd
0.15
-0.19
-55.88%

Beamtree Holdings Ltd Corporate Events

Beamtree Appoints Martin Bowles to Board Without Equity Stake
Mar 9, 2026

Beamtree Holdings Limited has announced the appointment of Martin Bowles as a director, effective 2 March 2026, and lodged the required initial director’s interest notice with the ASX. The filing confirms that Bowles currently holds no relevant interests in Beamtree securities and has no disclosed contractual interests, indicating his board role begins without an equity stake or related-party arrangements.

This governance update signals a change in the company’s board composition, which may shape future strategic direction and oversight without immediately altering the capital structure. Investors and other stakeholders may focus on Bowles’ background and potential influence on corporate decisions, although no additional details on his experience or intended contributions are provided in the notice.

The most recent analyst rating on (AU:BMT) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Mirrabooka Exits Substantial Holder Position in Beamtree After Corrected Filing
Mar 4, 2026

Mirrabooka Investments Limited has notified Beamtree Holdings Limited that it has ceased to be a substantial holder in the company as of 3 March 2026. The change was communicated through a corrected statutory notice, replacing an earlier version lodged the same day that contained inaccurate consideration figures in an annexure.

The updated filing confirms Mirrabooka’s reduced holding and voting interest in Beamtree, clarifying its current position in the register without altering the substance of the divestment. This adjustment provides more accurate disclosure for the market and shareholders, but the announcement does not indicate any direct changes to Beamtree’s operations or strategic direction.

The most recent analyst rating on (AU:BMT) stock is a Sell with a A$0.15 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Mirrabooka exits substantial holding in Beamtree Holdings
Mar 4, 2026

Mirrabooka Investments Limited has notified Beamtree Holdings Limited that it has ceased to be a substantial shareholder as of 3 March 2026, in line with Australian disclosure rules for significant holdings. The move follows a series of trades where Mirrabooka built its position in early 2024 before exiting through multiple share sales in February and March 2026, a change that may alter Beamtree’s institutional investor base and potentially affect the liquidity and composition of its share register.

Regulatory disclosure shows Mirrabooka initially increased its stake with several small and one large purchase of Beamtree shares in January and February 2024. Subsequent disposals, culminating in the sale of more than 18 million shares on 3 March 2026, reduced its holding below the substantial shareholder threshold, signalling a strategic portfolio adjustment by the investment firm rather than an announced change in Beamtree’s underlying operations.

The most recent analyst rating on (AU:BMT) stock is a Sell with a A$0.15 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Reshapes Board and Pay Structure as Strategic Review Begins
Mar 1, 2026

Beamtree Holdings has reshaped its governance structure as it undertakes a strategic review aimed at unlocking shareholder value, with Chair Emma Gray stepping into a time-limited Executive Chair role to oversee the process while CEO Marek Stepniak concentrates on accelerating international sales, particularly in the U.K. and Middle East. To align leadership with shareholder returns, Gray and all non-executive directors will receive their additional remuneration and board fees entirely in equity, subject to shareholder approval, while former Calvary Health Care chief executive and ex-Health Department secretary Martin Bowles joins the board, bringing significant healthcare sector expertise to support the company’s global growth ambitions.

The most recent analyst rating on (AU:BMT) stock is a Sell with a A$0.15 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Sets Date for 1H FY26 Results and Investor Webinar
Jan 28, 2026

Beamtree Holdings Limited has announced that it will release its half-year results for the first half of FY26 on 25 February 2026 and will host an investor webinar the same day at 9:00am AEST to discuss the performance. The scheduled update underscores the company’s ongoing communication with investors as it pursues growth in AI-enabled healthcare analytics and decision support, with stakeholders likely to focus on how its diversified product segments are translating into operational and financial progress in a competitive digital health landscape.

The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Seeks ASX Quotation for New Shares Issued Under Employee Plan
Jan 12, 2026

Beamtree Holdings Limited has applied for quotation on the ASX of 46,045 new fully paid ordinary shares issued on 13 January 2026 under its Employee Incentive Plan, pursuant to salary contribution arrangements. The modest equity issuance reflects the company’s ongoing use of share-based remuneration to align staff interests with shareholders, signalling continued emphasis on talent retention and engagement without materially altering the company’s capital structure.

The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Issues 1 Million Unquoted Performance Rights Under Employee Incentive Plan
Jan 12, 2026

Beamtree Holdings Limited has issued 1,000,000 unquoted performance rights under its employee incentive scheme, with the new securities designated under ASX code BMTAC and issued on 9 January 2026. The performance rights are subject to transfer restrictions and will not be quoted on the ASX until those restrictions lapse, indicating the company’s ongoing use of equity-based remuneration to retain and motivate staff while limiting immediate market dilution.

The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Issues 700,000 Unquoted Performance Rights Under Employee Incentive Scheme
Dec 19, 2025

Beamtree Holdings Limited has notified the market of the issue of 700,000 unquoted performance rights under its employee incentive scheme, with an issue date of 14 November 2025. The new equity allocation forms part of Beamtree’s strategy to align staff and executive remuneration with long-term shareholder value, using equity-based incentives that are subject to trading restrictions and are not quoted on the ASX, thereby reinforcing retention and performance objectives without immediately diluting the quoted share base.

The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 21, 2026